Caribou Biosciences, Inc. Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
Caribou Biosciences, Inc. (CRBU) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Percent of -1.50% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments · last filed 2026-03-05
- Caribou Biosciences, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2025 was -1.50%.
- Caribou Biosciences, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2023 was 0.00%, a 100.00% decline from fiscal 2022.
- Caribou Biosciences, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2022 was 1.00%.
- Caribou Biosciences, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2021 was 0.00%.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month |
|---|---|
| 2025-12-31 | -1.50% 10-K · filed 2026-03-05 |
| 2023-12-31 | 0.00% 10-K · filed 2024-03-11 |
| 2022-12-31 | 1.00% 10-K · filed 2024-03-11 |
| 2021-12-31 | 0.00% 10-K · filed 2023-03-09 |
| 2020-12-31 | -1.00% 10-K · filed 2022-03-21 |
| 2019-12-31 | 1.00% 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |